Publication Name	World Journal of Clinical Oncology
Manuscript ID	60254
Country	Pakistan

Received	2020-10-22 13:10
Peer-Review Started	2020-10-22 13:11
To Make the First Decision
Return for Revision	2020-12-03 18:13
Revised	2020-12-30 13:21
Second Decision	2021-04-08 12:36
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-04-08 16:20
Articles in Press	2021-04-08 16:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-05-07 15:12
Publish the Manuscript Online	2021-06-21 06:41

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Minireviews
Article Title	Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase
Manuscript Source	Unsolicited Manuscript
All Author List	Kashif Asghar, Asim Farooq, Bilal Zulfiqar and Asif Loya
Funding Agency and Grant Number
Corresponding Author	Kashif Asghar, DVM, PhD, Research Scientist, Department of Basic Science Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre 7A, Block R3, Johar Town, Lahore 54000, Pakistan. drkashifasghar@gmail.com
Key Words	Indoleamine 2, 3-dioxygenase; Breast cancer; Therapeutic target; Prognostic marker; Immune responses; Immune escape
Core Tip	Indoleamine 2,3-dioxygenase might be utilized as a potential biomarker and immunotherapeutic target in breast cancer patients.
Publish Date	2021-06-21 06:41
Citation	Asghar K, Farooq A, Zulfiqar B, Loya A. Review of 10 years of research on breast cancer patients: Focus on indoleamine 2, 3-dioxygenase. World J Clin Oncol 2020; 12(6): 429-436
URL	https://www.wjgnet.com/2218-4333/full/v12/i6/429.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i6.429

Full Article (PDF)	WJCO-12-429.pdf
Full Article (Word)	WJCO-12-429.docx
Manuscript File	60254_Auto_Edited_LM.docx
Answering Reviewers	60254-Answering reviewers.pdf
Audio Core Tip	60254-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	60254-Conflict-of-interest statement.pdf
Copyright License Agreement	60254-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	60254-Language certificate.pdf
Peer-review Report	60254-Peer-review(s).pdf
Scientific Misconduct Check	60254-CrossCheck.png
Scientific Misconduct Check	60254-Bing-Gong ZM-1.png
Scientific Misconduct Check	60254-Scientific misconduct check.pdf
Scientific Editor Work List	60254-Scientific editor work list.pdf